One dose, one billion girls: the scientific and public health imperative of India’s single dose human Papillomavirus vaccination strategy

Meenakshi Khapre; Anjali Mukkunnoth

doi:10.18203/2394-6040.ijcmph20263246

Authors

Meenakshi Khapre Department of Community Medicine, AIIMS, Rishikesh, Uttarakhand, India
Anjali Mukkunnoth Department of Community Medicine, Kasturba Medical College, Mangalore, Karnataka, India

DOI:

https://doi.org/10.18203/2394-6040.ijcmph20263246

Keywords:

Cervical cancer , HPV, UIP

Abstract

Cervical cancer remains one of the leading causes of cancer mortality in women across low- and middle-income countries (LMICs). In India, an estimated 1,27,526 new cases and 79,906 deaths were recorded in 2022, accounting for approximately 19% of the global burden.¹ Every day, nearly 200 Indian women lose their lives to a disease that a vaccine can prevent. Against this backdrop, the phased introduction of the human Papillomavirus (HPV) vaccine under India's Universal Immunisation Programme (UIP), following the Union Budget announcement in February 2024 and sustained advocacy by the National Technical Advisory Group on Immunisation (NTAGI), represents a watershed moment in preventive oncology.

Author Biography

Meenakshi Khapre, Department of Community Medicine, AIIMS, Rishikesh, Uttarakhand, India

Community Medicine

References

Global Cancer Observatory. Cancer Today. Lyon: International Agency for Research on Cancer. 2022. Available at: https://gco.iarc.who.int/today. Accessed on 18 May 2026.

National Technical Advisory Group on Immunization (NTAGI). 17th NTAGI Meeting Recommendations. New Delhi: Ministry of Health and Family Welfare; 2022.

World Health Organization. Human papillomavirus vaccines: WHO position paper, December 2022. Wkly Epidemiol Rec. 2022;97(50):645-72.

Wu S, Deng Y, Lepp T, Schollin Ask L, Sparen P, Clements M, et al. Extended follow-up of invasive cervical cancer risk after quadrivalent HPV vaccination: a nationwide register-based study. BMJ. 2026;392:e087326.

Basu P, Malvi SG, Joshi S, Bhatla N, Muwonge R, Lucas E, et al. Vaccine efficacy against persistent human papillomavirus (HPV) 16/18 infection at 10 years after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre, prospective, cohort study. Lancet Oncol. 2021;22(11):1518-29.

Barnabas RV, Brown ER, Onono MA, Bukusi EA, Njoroge B, Winer RL, et al. Efficacy of single-dose HPV vaccination among young African women. N Engl J Med. 2022;387(3):213-23.

Nygård S, Falkenthal TEH, Sture T, Lynge E, Elfström M, Nygård M. Impact of multicohort human papillomavirus vaccination on cervical cancer in women below 30 years of age: lessons learned from the Scandinavian countries. J Infect Dis. 2025;231(3):e497-500.

World Health Organization. Global strategy to accelerate the elimination of cervical cancer as a public health problem. 2020. Available at: https://www.who.int/publications/i/item/9789240014107. Accessed on 15 May 2026.

Bhattacharya S, Garg S. Empowering India's fight against cervical cancer: harnessing routine HPV immunisation. J Family Med Prim Care. 2025;14(1):22-8.

Abbas KM, van Zandvoort K, Brisson M, Jit M. Effects of updated COVID-19 vaccination schedules on herd immunity and cost-effectiveness in India: a modelling study. Lancet Oncol. 2022;23(11):1419-31.

Schuind AE, Balaji KA, Du A, Yuan Y, Dull P. Human papillomavirus prophylactic vaccines: update on new vaccine development and implications for single-dose policy. JNCI Monogr. 2024;2024(67):410-6.